Preclinical Studies

A pile of cocaine hydrochloride. Credit: DEA Drug Enforcement Agency, public domain Researchers at the Medical University of South Carolina (MUSC) have used viruses to infect neurons with genes that allow them to switch on brain receptors involved in suppressing addiction relapse. Results of these preclinical studies were published in the September 28th, 2016 issue […]

Glioblastoma (histology slide). Credit: Wikipedia/CC BY-SA 3.0 Investigational “hunter” immune cells engineered to seek out and attack a deadly brain cancer known as glioblastoma (GBM) infiltrated patients’ tumors and triggered thousands of more T cells once inside, researchers from Penn Medicine reported in a late breaking abstract at the AACR Annual Meeting 2017 (Abstract LB-053). […]

A well-known rheumatoid arthritis medication containing the active agent adalimumab, a therapeutic human monoclonal antibody, is also effective for treating non-infectious uveitis, a rare eye disease. This has now been discovered … … read more at: https://medicalxpress.com/news/2017-03-tocilizumab-uveitis-juvenile-idiopathic-arthritis.html

The largest CBD study presented efficacy and safety data on GW Pharmaceutical’s investigational medicine, Epidiolex (cannabidiol) from open-label Expanded Access programs at 16 sites. The study (abstract 3.034) involves 261 people, predominantly children, who have severe epilepsy that had not responded adequately to other treatments. The average age of the participants was 11. Over the […]


Warning: preg_replace() [function.preg-replace]: Unknown modifier '1' in /home/content/96/5373796/html/cbdcasestudies.com/wp-content/plugins/jetpack/class.photon.php on line 345

Puriskin by Vanessa Blake Cosmetics enter the pain-relief and CBD Market NEW YORK, NEW YORK (NY), UNITED STATES, April 3, 2017 /EINPresswire.com/ — Natural, British skincare brand Puriskin by Vanessa Blake Cosmetics, widen their market reach with an expansion into the pain-relief sector and the rapidly evolving CBD industry. Puriskin CBD Therapy, is the emerging wellness […]

Canadian researchers are testing mice to see if cannabinoid oil products — a common medical marijuana treatment — could help alleviate the neuropathic pain that often afflicts patients with multiple sclerosis (MS). The preclinical study, “Identifying the molecular mechanisms involved in supressing multiple sclerosis induced neuropathic pain following cannabinoid treatment in an animal model of multiple sclerosis (MS),” […]

by

NEW YORK, March 01, 2017 (GLOBE NEWSWIRE) — AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, began production of CanChew Plus™, the next generation of the company’s award-winning controlled-release cannabidiol (CBD) functional chewing gum. CanChew® is the world’s first patented controlled-release cannabinoid chewing gum containing 50 mg of hemp […]

Editorial: J. Stephen McIver, EditorAdvertising: Maureen Dwyer Liberti, Vice President, Group PublisherProduction: Dawn Flook, Director of Production ServicesCirculation: Jackie Ott, Circulation ManagerWebmaster: Webmaster … read more at: https://www.ptcommunity.com/news/20170206/biopharma-companies-mix-medications-and-cannabis

Daily consumption of krill oil may boost learning and working memory in lab animals, and display antidepressant-like effects, according to a new study from Aker BioMarine. Lab rats who received daily krill oil supplements (Superba krill oil, Aker) performed better in cognitive tests, compared to control animals, according to findings published in Lipids in Health […]

The FDA has given clearance to NeuroRx to proceed with a phase 2B/3 study protocol under an investigational new drug application for NRX-101, the first oral therapy for acute suicidal ideation and behavior (ASIB). The goal of the trials is to exhibit the effectiveness and safety of NRX-101 as a means of maintaining remission in patients […]

by

(Reuters) – BioCryst Pharmaceuticals Inc said on Monday a dose of its experimental antiviral drug improved survival rates in mice infected with the Zika virus in a preclinical study. Two doses of the drug, BCX443, were tested against a placebo and an oral antiviral called ribavarin for their effect on survival of immune-deficient mice infected […]

by